title: [Angiotensin receptor vaccines].
abstract: Recent clinical studies have shown that RAS inhibitors are effective not only for the prevention of end-organ damage in hypertensive patients, but also for prevention of new-onset hypertension, diabetes mellitus, and atrial fibrillation. Vaccines against the RAS have been developed since the 1950s, and a recent phase IIa placebo-controlled study has confirmed that an angiotensin vaccine causes a significant decrease in blood pressure in hypertensive patients. The results of animal experiments from our and other laboratories have suggested that vaccination against the angiotensin type 1 (AT1) receptor causes a significant decrease in blood pressure in animal models of hypertension, and also ameliorates hypertensive end-organ damage. The angiotensin receptor may therefore be an important target for the development of vaccines for the prevention of hypertension and related complications.
authors.affiliation: Department of Internal Medicine, Keio University.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Sasamura
authors.forename: Tatsuhiko
authors.initials: T
authors.lastname: Azegami
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Itoh
mesh_terms: D006801:Humans; D006973:Hypertension / Q000628:therapy*; D011945:Receptors, Angiotensin / Q000276:immunology*
chemical_list: D011945:Receptors, Angiotensin